Vestnik dermatologii i venerologiiVestnik dermatologii i venerologiiВестник дерматологии и венерологии0042-46092313-6294Rossijskoe Obschestvo Dermatovenerologov i Kosmetologov129410.25208/vdv1294REVIEWSОБЗОР ЛИТЕРАТУРЫReview ArticleNon-surgical treatments for basal cell skin cancerВозможности нехирургических методов лечения базальноклеточного рака кожиhttps://orcid.org/0000-0002-7625-05038771-4990KubanovAlexey A.КубановАлексей Алексеевич
Russian Federation

MD, Dr. Sci. (Med.), Professor, Corresponding Member of the Russian Academy of Sciences

д.м.н., профессор, член-корреспондент РАН

alex@cnikvi.ruhttps://orcid.org/0000-0001-6132-56321149-2097SaytburkhanovRifat R.СайтбурхановРифат Рафаилевич
Russian Federation

dermatovenereologist

врач-дерматовенеролог

rifat03@yandex.ruhttps://orcid.org/0000-0003-4169-41287634-5521PlakhovaXenia I.ПлаховаКсения Ильинична
Russian Federation

MD, Dr. Sci. (Med.)

д.м.н.

plahova@cnikvi.ruhttps://orcid.org/0000-0003-3662-99548721-9424KondrakhinaIrina N.КондрахинаИрина Никифоровна
Russian Federation

MD, Cand. (Sci.) Med.

к.м.н.

kondrakhina77@gmail.comState Research Center of Dermatovenereology and CosmetologyГосударственный научный центр дерматовенерологии и косметологии2412202197620321411202128122021Copyright ©; 2021, Kubanov A.A., Saytburkhanov R.R., Plakhova X.I., Kondrakhina I.N.Copyright ©; 2021, Кубанов А.А., Сайтбурханов Р.Р., Плахова К.И., Кондрахина И.Н.2021Kubanov A.A., Saytburkhanov R.R., Plakhova X.I., Kondrakhina I.N.Кубанов А.А., Сайтбурханов Р.Р., Плахова К.И., Кондрахина И.Н.https://creativecommons.org/licenses/by/4.0https://vestnikdv.ru/jour/article/view/1294

Basal cell carcinoma is the most common nonmelanoma skin cancer. It originates from undifferentiated cells in the basal cell layer of the epidermis or from the outer root sheath of the hair follicle. The most important factor in development of basalioma is ultraviolet radiation. Surgery is considered the gold standard of treatment for basal cell cancer. However, nonsurgical options are available for individuals who are unsuitable for surgery. The purpose of this review is to summarize the efficacy and indications of alternative, nonsurgical treatments that can be used in the management of basal cell cancer

Effective nonsurgical treatments include destructive methods (eg, curettage and electrodessication, cryosurgery, laser), photodynamic therapy, topical medications, hedgehog pathway inhibitors. Nonsurgical therapeutic alternatives are safe and effective for the treatment of BCC. Factors such as tumor location, size, and histopathological subtype should be taken into consideration when selecting optimal treatment, cosmetic results and patient preference should be considered too.

To search for the necessary literature, the PubMed, MedLine, Web of Science and RSCI databases were used.

Базальноклеточная карцинома является наиболее распространенным немеланомным раком кожи. Он происходит из недифференцированных клеток базального слоя эпидермиса или из внешней корневой оболочки волосяного фолликула. Важнейшим этиологическим фактором развития базалиомы является ультрафиолетовое излучение.

Хирургическое лечение считается золотым стандартом лечения пациентов с базальноклеточным раком кожи, тем не менее в ситуациях, когда хирургический метод лечения невозможен, доступны нехирургические варианты. Цель этого обзора — обобщить эффективность и показания к альтернативным нехирургическим методам лечения, которые могут быть использованы при лечении пациентов с базальноклеточным раком кожи.

Эффективные нехирургические методы лечения базальноклеточного рака кожи включают деструктивные методы (выскабливание и электродессикация, криохирургия, лазерная деструкция), фотодинамическую и наружную терапию, ингибиторы сигнального пути Hedgehog. Нехирургические альтернативы могут быть безопасны и эффективны для лечения базальноклеточного рака кожи. При выборе оптимального лечения следует учитывать такие факторы, как расположение, размер и гистопатологический подтип опухоли, а также следует учитывать ожидаемые косметические результаты и предпочтения пациента.

Для поиска необходимой литературы использованы базы данных PubMed, MedLine, Web of Science и РИНЦ.

basal cell skin cancerdestructive methodsphotodynamic therapylaserhedgehog pathway inhibitorsбазальноклеточный рак кожидеструктивные методыфотодинамическая терапиялазерингибиторы сигнального пути HedgehogPrieto-Granada C, Rodriguez-Waitkus P. Basal cell carcinoma: Epidemiology, clinical and histologic features, and basic science overview. Curr Probl Cancer. 2015;39(4):198–205. doi: 10.1016/j.currproblcancer.2015.07.004Marzuka AG, Book SE. Basal cell carcinoma: pathogenesis, epidemiology, clinical features, diagnosis, histopathology, and management. Yale J Biol Med. 2015;88(2):167–179.Zanetti R, Rosso S, Martinez C, Nieto A, Miranda A, Mercier M, et al. Comparison of risk patterns in carcinoma and melanoma of the skin in men: a multi-centre case-case-control study. Br J Cancer. 2006;94(5):743–751. doi: 10.1038/sj.bjc.6602982Correia de Sá TR, Silva R, Lopes JM. Basal cell carcinoma of the skin (part 1): epidemiology, pathology and genetic syndromes. Future Oncol. 2015;11(22):3011–3021. doi: 10.2217/fon.15.246López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153(6):1194–1217. doi: 10.1016/j.cell.2013.05.039Green A, Williams G, Neale R, Hart V, Leslie D, Parsons P, Marks GC, Gaffney P, Battistutta D, Frost C, Lang C, Russell A. Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: a randomised controlled trial. Lancet. 1999;354(9180):723–729. doi: 10.1016/S0140-6736(98)12168-2Ulrich C, Jürgensen JS, Degen A, Hackethal M, Ulrich M, Patel MJ, Eberle J, Terhorst D, Sterry W, Stockfleth E. Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. Br J Dermatol. 2009;161 Suppl 3:78–84. doi: 10.1111/j.1365-2133.2009.09453.xКаприн А.Д., Старинский В.В., Шахзадова А.О. Злокачественные новообразования в России в 2019 году (заболеваемость и смертность). — 2020. [Kaprin AD, Starinskij VV, Shahzadova AO. Zlokachestvennye novoobrazovanija v Rossii v 2019 godu (zabolevaemost' i smertnost'). — 2020 (In Russ.)]Apalla Z, Nashan D, Weller RB, Castellsagué X. Skin Cancer: Epidemiology, Disease Burden, Pathophysiology, Diagnosis, and Therapeutic Approaches. Dermatol Ther (Heidelb). 2017;7(Suppl 1):5–19. doi:10.1007/s13555-016-0165-yScrivener Y, Grosshans E, Cribier B. Variations of basal cell carcinomas according to gender, age, location and histopathological subtype. Br J Dermatol. 2002;147(1):41–47. doi: 10.1046/j.1365-2133.2002.04804.xGandhi SA, Kampp J. Skin Cancer Epidemiology, Detection, and Management. Med Clin North Am. 2015;99(6):1323–1335. doi: 10.1016/j.mcna.2015.06.002McCormack CJ, Kelly JW, Dorevitch AP. Differences in age and body site distribution of the histological subtypes of basal cell carcinoma. A possible indicator of differing causes. Arch Dermatol. 1997;133(5):593–596.Цветкова Г.М., Мордовцева В.В., Вавилов А.М., Мордовцев В.Н. (2003). Патоморфология болезней кожи. М.: Медицина. [Cvetkova GM, Mordovceva VV, Vavilov AM, Mordovcev VN. (2003). Patomorfologija boleznej kozhi. Moscow: Medicina (In Russ.)]Галил-Оглы Г.А., Молочков В.А., Сергеев Ю.В. (2005). Дерматоонкология. М.: Медицина для всех, 628. [Galil-Ogly GA, Molochkov VA, Sergeev JuV. (2005). Dermatoonkologija. Moscow: Medicina dlja vseh, 628 (In Russ.)]Sloane JP. (1977). The value of typing basal cell carcinomas in predicting recurrence after surgical excision. British Journal of Dermatology, 96(2);127–132.Neugut AI, Robinson E. (1992). Multiple primary neoplasms. The Cancer journal (Print),5(5),245–248.Elston DM, Stratman EJ, Miller SJ. Skin biopsy: Biopsy issues in specific diseases. J Am Acad Dermatol. 2016;74(1):1-16; quiz 17–18. doi: 10.1016/j.jaad.2015.06.033Sexton M, Jones DB, Maloney ME. Histologic pattern analysis of basal cell carcinoma. Study of a series of 1039 consecutive neoplasms. J Am Acad Dermatol. 1990;23(6 Pt 1):1118–26. doi: 10.1016/0190-9622(90)70344-hCrowson AN. (2006). Basal cell carcinoma: biology, morphology and clinical implications. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc, 19 Suppl 2, S127–S147. doi: 10.1038/modpathol.3800512Bichakjian CK, Olencki T, Aasi SZ. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Basal Skin Cancer, V.1; 2018. Available from: https://www.nccn.org/professionals/physician_gls/pdf/nmsc.pdfАлиев М.Д., Алиева С.Д, Алымов Ю.В., Бохян Б.Ю., Гафтон Г.И., Демидов Л.В. (2020). Клинические рекомендации. Базальноклеточный рак кожи. Ассоциация онкологов России. Электронный ресурс. URL: https://oncology-association.ru/wp-content/uploads/2020/09/bazalnokletochnyj_rak.pdf [Aliev MD, Alieva SD, Alymov JuV, Bohjan BJu, Gafton GI, Demidov LV (2020). Klinicheskie rekomendacii Bazal'nokletochnyj rak kozhi. Associacija onkologov Rossii (In Russ.)]Lott DG, Manz R, Koch C, Lorenz RR. Aggressive behavior of nonmelanotic skin cancers in solid organ transplant recipients. Transplantation. 2010;90(6):683–687. doi: 10.1097/TP.0b013e3181ec7228Archier E, Devaux S, Castela E, Gallini A, Aubin F, Le Maître M, et al. (2012). Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review. Journal of the European Academy of Dermatology and Venereology: JEADV, 26 Suppl 3, 22–31. doi: 10.1111/j.1468-3083.2012.04520.xSartore L, Lancerotto L, Salmaso M, Giatsidis G, Paccagnella O, Alaibac M, et al. (2011). Facial basal cell carcinoma: analysis of recurrence and follow-up strategies. Oncology reports, 26(6),1423–1429. doi: 10.3892/or.2011.1453Cameron MC, Lee E, Hibler BP, Giordano CN, Barker CA, Mori S, Cordova M, Nehal KS & Rossi AM. (2019). Basal cell carcinoma: Contemporary approaches to diagnosis, treatment, and prevention. Journal of the American Academy of Dermatology, 80(2):321–339. https://doi.org/10.1016/j.jaad.2018.02.083Dunn M, Morgan MB, Beer TW. Perineural invasion: identification, significance, and a standardized definition. Dermatol Surg. 2009;35(2):214–221. doi: 10.1111/j.1524-4725.2008.34412.xWork Group; Invited Reviewers, Kim JYS, Kozlow JH, Mittal B, Moyer J, Olencki T, Rodgers P. Guidelines of care for the management of basal cell carcinoma. J Am Acad Dermatol. 2018 Mar;78(3):540–559. doi: 10.1016/j.jaad.2017.10.006Goldman G. (2002). The current status of curettage and electrodesiccation. Dermatologic clinics, 20(3),569–ix. doi:10.1016/s0733-8635(02)00022-0Silverman MK, Kopf AW, Grin CM, Bart RS, Levenstein MJ. Recurrence rates of treated basal cell carcinomas. Part 2: Curettage-electrodesiccation. J Dermatol Surg Oncol. 1991;17(9):720–726. doi: 10.1111/j.1524-4725.1991.tb03425.xAdam JE. The technic of curettage surgery. J Am Acad Dermatol. 1986;15(4 Pt 1):697–702. doi: 10.1016/s0190-9622(86)70226-0Rodriguez-Vigil T, Vázquez-López F, Perez-Oliva N. Recurrence rates of primary basal cell carcinoma in facial risk areas treated with curettage and electrodesiccation. J Am Acad Dermatol. 2007;56(1):91–95. doi: 10.1016/j.jaad.2006.07.007Ахтямов С.Н. Электро- и радиохирургические методы в дерматологии и косметологии. Методическое пособие. 2014. 67 с. [Ahtjamov SN. Jelektro- i radiohirurgicheskie metody v dermatologii i kosmetologii. Metodicheskoe posobie. 2014. 67s. (In Russ.)] http://www.mtucimed.ru/files/Ahtyamov.pdfKuflik EG. Cryosurgery for cutaneous malignancy. An update. Dermatol Surg. 1997;23(11):1081–1087. doi: 10.1111/j.1524-4725.1997.tb00453.x.Kuflik EG. Cryosurgery for skin cancer: 30-year experience and cure rates. Dermatol Surg. 2004;30(2 Pt 2):297–300. doi: 10.1111/j.1524-4725.2004.30090.x.Lindemalm-Lundstam B, Dalenbäck J. Prospective follow-up after curettage-cryosurgery for scalp and face skin cancers. Br J Dermatol. 2009;161(3):568–576. doi: 10.1111/j.1365-2133.2009.09310.xPaoli J, Gyllencreutz JD, Fougelberg J, Backman EJ, Modin M, Polesie S, Zaar O. Nonsurgical Options for the Treatment of Basal Cell Carcinoma. Dermatol Pract Concept. 2019;9(2):75–81. doi: 10.5826/dpc.0902a01Buckley D. Re: The freeze-thaw cycle in cryosurgery. J Eur Acad Dermatol Venereol. 2017;31(9):e405-e406. doi: 10.1111/jdv.14215Buckley D. Cryosurgery for Nonmelanoma Skin Cancer. In Modern cryosurgery for cancer. 2012;865–892.Zacarian SA. Cryosurgery of cutaneous carcinomas. An 18-year study of 3,022 patients with 4,228 carcinomas. J Am Acad Dermatol. 1983;9(6):947–56. doi: 10.1016/s0190-9622(83)70213-6Campolmi P, Brazzini B, Urso C, Ghersetich I, Mavilia L, Hercogova J, Lotti T. Superpulsed CO2 laser treatment of basal cell carcinoma with intraoperatory histopathologic and cytologic examination. Dermatol Surg. 2002;28(10):909–911; discussion 912. doi: 10.1046/j.1524-4725.2002.02076.xKavoussi H, Ebrahimi A. Treatment and cosmetic outcome of superpulsed CO2 laser for basal cell carcinoma. Acta Dermatovenerol Alp Pannonica Adriat. 2013;22(3):57–61.Sharon E, Snast I, Lapidoth M, Kaftory R, Mimouni D, Hodak E, Levi A. Laser Treatment for Non-Melanoma Skin Cancer: A Systematic Review and Meta-Analysis. Am J Clin Dermatol. 2021;22(1):25–38. doi: 10.1007/s40257-020-00562-8Smucler R, Vlk M. Combination of Er:YAG laser and photodynamic therapy in the treatment of nodular basal cell carcinoma. Lasers Surg Med. 2008;40(2):153–158. doi: 10.1002/lsm.20606Soleymani T, Abrouk M, Kelly KM. An Analysis of Laser Therapy for the Treatment of Nonmelanoma Skin Cancer. Dermatol Surg. 2017;43(5):615–624. doi: 10.1097/DSS.0000000000001048Konnikov N, Avram M, Jarell A, Tannous Z. Pulsed dye laser as a novel non-surgical treatment for basal cell carcinomas: response and follow up 12-21 months after treatment. Lasers Surg Med. 2011;43(2):72–78. doi: 10.1002/lsm.21035.Ballard CJ, Rivas MP, McLeod MP, Choudhary S, Elgart GW, Nouri K. The pulsed dye laser for the treatment of basal cell carcinoma. Lasers Med Sci. 2011;26(5):641–644. doi: 10.1007/s10103-011-0952-8Moskalik K, Kozlow A, Demin E, Boiko E. Powerful neodymium laser radiation for the treatment of facial carcinoma: 5 year follow-up data. Eur J Dermatol. 2010(6):738–742. doi: 10.1684/ejd.2010.1055Foley P, Freeman M, Menter A, Siller G, El-Azhary RA, Gebauer K, et al. Photodynamic therapy with methyl aminolevulinate for primary nodular basal cell carcinoma: results of two randomized studies. Int J Dermatol. 2009;48(11):1236–1245. doi: 10.1111/j.1365-4632.2008.04022.xOseroff A. PDT as a cytotoxic agent and biological response modifier: Implications for cancer prevention and treatment in immunosuppressed and immunocompetent patients. J Invest Dermatol. 2006;126(3):542–544. doi: 10.1038/sj.jid.5700207Filonenko E, Kaprin A, Urlova A, Grigorievykh N, Ivanova-Radkevich V. Topical 5-aminolevulinic acid-mediated photodynamic therapy for basal cell carcinoma. Photodiagnosis Photodyn Ther. 2020;30:101644. doi: 10.1016/j.pdpdt.2019.101644Schleier P, Berndt A, Kolossa S, Zenk W, Hyckel P, Schultze-Mosgau S. Comparison of aminolevulinic acid (ALA)-thermogel-PDT with methyl-ALA-thermogel-PDT in basal cell carcinoma. Photodiagnosis Photodyn Ther. 2007;4(3):197–201. doi: 10.1016/j.pdpdt.2007.04.004Basset-Seguin N, Ibbotson SH, Emtestam L, Tarstedt M, Morton C, Maroti M, et al. Topical methyl aminolaevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial. Eur J Dermatol. 2008;18(5):547–553. doi: 10.1684/ejd.2008.0472Christensen E, Skogvoll E, Viset T, Warloe T, Sundstrøm S. Photodynamic therapy with 5-aminolaevulinic acid, dimethylsulfoxide and curettage in basal cell carcinoma: a 6-year clinical and histological follow-up. J Eur Acad Dermatol Venereol. 2009;23(1):58–66. doi: 10.1111/j.1468-3083.2008.02946.xWang H, Xu Y, Shi J, Gao X, Geng L. Photodynamic therapy in the treatment of basal cell carcinoma: a systematic review and meta-analysis. Photodermatol Photoimmunol Photomed. 2015;31(1):44–53. doi: 10.1111/phpp.12148Parker WB, Cheng YC. Metabolism and mechanism of action of 5-fluorouracil. Pharmacol Ther. 1990;48(3):381–395. doi: 10.1016/0163-7258(90)90056-8Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3(5):330–338. doi: 10.1038/nrc1074Moore AY. Clinical applications for topical 5-fluorouracil in the treatment of dermatological disorders. J Dermatolog Treat. 2009;20(6):328–335. doi: 10.3109/09546630902789326Gross K, Kircik L, Kricorian G. 5% 5-Fluorouracil cream for the treatment of small superficial Basal cell carcinoma: efficacy, tolerability, cosmetic outcome, and patient satisfaction. Dermatol Surg. 2007;33(4):433–439; discussion 440. doi: 10.1111/j.1524-4725.2007.33090.xRoozeboom MH, Arits AHMM, Mosterd K, Sommer A, Essers BAB, de Rooij MJM, et al. Three-Year Follow-Up Results of Photodynamic Therapy vs. Imiquimod vs. Fluorouracil for Treatment of Superficial Basal Cell Carcinoma: A Single-Blind, Noninferiority, Randomized Controlled Trial. J Invest Dermatol. 2016;136(8):1568–1574. doi: 10.1016/j.jid.2016.03.043Love WE, Bernhard JD, Bordeaux JS. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review. Arch Dermatol. 2009;145(12):1431–1438. doi: 10.1001/archdermatol.2009.291Jansen M, Mosterd K, Arits A, Roozeboom MH, Sommer A, Essers B, et al. Five-Year Results of a Randomized Controlled Trial Comparing Effectiveness of Photodynamic Therapy, Topical Imiquimod, and Topical 5-Fluorouracil in Patients with Superficial Basal Cell Carcinoma. The Journal of investigative dermatology.2018,138(3):527–533. doi: 10.1016/j.jid.2017.09.033Bath-Hextall F, Ozolins M, Armstrong SJ, Colver GB, Perkins W, Miller PS, et al; Surgery versus Imiquimod for Nodular Superficial basal cell carcinoma (SINS) study group. Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial. Lancet Oncol. 2014;15(1):96–105. doi: 10.1016/S1470-2045(13)70530-8Gutzmer R, Solomon JA. Hedgehog Pathway Inhibition for the Treatment of Basal Cell Carcinoma. Target Oncol. 2019;14(3):253–267. doi: 10.1007/s11523-019-00648-2ClinicalTrials.gov Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syn-Drome Patients—Full Text View. Available online: https://clinicaltrials.gov/ct2/show/NCT02762084.ClinicalTrials.gov Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas — Full Text View. Available online: https://clinicaltrials.gov/ct2/show/NCT02828111.ClinicalTrials.gov A Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients with Non-Gorlin High Frequency BCC—Full Text View. Available online: https://clinicaltrials.gov/ct2/show/NCT04155190.Peris K, Licitra L, Ascierto PA, Corvò R, Simonacci M, Picciotto F, et al. Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: an expert panel consensus. Future oncology (London, England), 11(4):703–712. doi: 10.2217/fon.14.281Axelson M, Liu K, Jiang X, He K, Wang J, Zhao H, et al. U.S. Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma. Clinical cancer research: an official journal of the American Association for Cancer Research, 19(9):2289–2293. doi: 10.1158/1078-0432.CCR-12-1956Sekulic A, Migden MR, Basset-Seguin N, Garbe C, Gesierich A, Lao CD., et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC cancer. 17(1):332. doi: 10.1186/s12885-017-3286-5Basset-Séguin N, Hauschild A, Kunstfeld R, Grob J, Dréno B, et al. Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial. European journal of cancer (Oxford, England: 1990),86:334–348. doi: 10.1016/j.ejca.2017.08.022Mohan SV, Chang J, Li S, Henry AS, Wood DJ, Chang AL. Increased Risk of Cutaneous Squamous Cell Carcinoma After Vismodegib Therapy for Basal Cell Carcinoma. JAMA dermatology. 152(5);527–532. doi: 10.1001/jamadermatol.2015.4330Casey D, Demko S, Shord S, Zhao H, Chen H, He K, et al. FDA Approval Summary: Sonidegib for Locally Advanced Basal Cell Carcinoma. Clin Cancer Res. 2017;23(10):2377–2381. doi: 10.1158/1078-0432.CCR-16-2051Migden MR, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P, et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. The Lancet. Oncology. 16(6),716–728. doi:10.1016/S1470-2045(15)70100-2Atwood SX, Chang AL, Oro AE. Hedgehog pathway inhibition and the race against tumor evolution. J Cell Biol. 2012;199(2):193–197. doi: 10.1083/jcb.201207140Dong X, Wang C, Chen Z, Zhao W. Overcoming the resistance mechanisms of Smoothened inhibitors. Drug Discov Today. 2018;23(3):704–710. doi: 10.1016/j.drudis.2018.01.012Bendell J, Andre V, Ho A, Kudchadkar R, Migden M, Infante J, et al. Phase I Study of LY2940680, a Smo Antagonist, in Patients with Advanced Cancer Including Treatment-Naïve and Previously Treated Basal Cell Carcinoma. Clin Cancer Res. 2018;24(9):2082–2091. doi: 10.1158/1078-0432.CCR-17-0723